Generic drugmaker Viatris has become the first company to secure FDA approval for a biosimilar product that is considered completely interchangeable with the reference product – namely Sanofi's ...

SaveHealth reports that insulin therapy is crucial for diabetes management, with various options available, including rapid- ...

CivicaScript, a nonprofit generic drug company, has launched insulin glargine-yfgn and ustekinumab-aauz, expanding its national portfolio of low-cost treatments. The insulin product, which is ...

California is the first state in the country to partner with a nonprofit to develop, produce and sell its own insulin.

As of January, California is the first state in the country to partner with a nonprofit to develop, produce and sell its own ...

The new year will begin with some first-of-their-kind laws in several states. Hawaii will become the first state to raise its ...

In Utah, people who party too heartily — and get caught driving drunk — could be among the first to have their driver's ...

In a move aimed at expanding affordable treatment options for millions of Americans living with diabetes, Biocon Biologics Ltd. and nonprofit generic drug manufacturer Civica, Inc. have announced a ...

Civica plans to distribute its insulin glargine to pharmacies across the United States for $45 for a box of five pens. “Through the partnership we formed with Civica more than six years ago, BCBSA and ...

Biocon Biologics Ltd., a unit of India’s Biocon Ltd., has expanded its partnership with US-based nonprofit Civica Inc. to launch a private-label version of insulin glargine in the United States, ...